title: ALK inhibitors: plateauing systemic and intracranial activity?
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: dbcosta@bidmc.harvard.edu.
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Costa
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung; D006801:Humans; D008175:Lung Neoplasms; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D020794:Receptor Protein-Tyrosine Kinases
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D020794:Receptor Protein-Tyrosine Kinases